Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 1.00 |
| ▸ | NPC1 | O15118 | 13/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.96 |
| ▸ | HPGD | P15428 | 6/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.96 |
| ▸ | MAPT | P10636 | 2/20 | 0.96 |
| ▸ | GLA | P06280 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.96 |
| ▸ | MECP2 | P51608 | 1/20 | 0.69 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.64 |
| ▸ | RELA | Q04206 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601473 | 0.91 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4343181 | 0.89 | NPC1 (0.94) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL522555 | 0.86 | NPC1 (0.90) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL46424 | 0.86 | NPC1 (0.90) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22858502 | 0.86 | NPC1 (0.90) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL74999 | 0.86 | NPC1 (0.90) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL46426 | 0.86 | NPC1 (1.00) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1142913 | 0.84 | MECP2 (0.83) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11508555 | 0.84 | MECP2 (0.83) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1105099 | 0.84 | NPC1 (0.85) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312491-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-05 | — | — | US | claimed |
| EP-4251614-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | claimed |
| CN-116457353-A | N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | claimed |
| WO-2022112139-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | claimed |
| CN-1288151-C | Metal complex type luminous material containing electron injection group and its preparation method | UNIV SHANXI (CN) | 2006-12-06 | — | — | CN | claimed |
| CN-1597682-A | Metal complex type luminous material containing electron injection group and its preparation method | UNIV SHANXI (CN) | 2005-03-23 | — | — | CN | claimed |
| US-20230312491-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312491-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230312491-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4251614-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| CN-116457353-A | N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2022112139-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022112139-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-7723336-B2 | Fused heterocyclic compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| CN-1288151-C | Metal complex type luminous material containing electron injection group and its preparation method | UNIV SHANXI (CN) | 2006-12-06 | — | — | CN | disclosed |
| CN-1597682-A | Metal complex type luminous material containing electron injection group and its preparation method | UNIV SHANXI (CN) | 2005-03-23 | — | — | CN | disclosed |
| CN-1597682-A | Metal complex type luminous material containing electron injection group and its preparation method | UNIV SHANXI (CN) | 2005-03-23 | — | — | CN | disclosed |
| US-5707779-A | DYE MOLECULES | KABUSHIKI KAISHA TOSHIBA (JP) | 1998-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045536-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP3K3, MAP3K2, MAP4K3 | RAB9A 1376/4885NPC1 4202/4885MEN1 1632/4885 |
| US-20230312491-A1 | N-SUBSTITUTED 4-(5-PHENYL-1,3,4-OXADIAZOL-2-YL)ANILINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | SLC10A1, HAVCR2, CYP4B1 | RAB9A 2865/4885NPC1 106/4885MEN1 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.